ArticleHuman cell2026
SAT1 promotes prostate cancer progression and decreases enzalutamide sensitivity by enhancing spermine catabolism.
Article in Human cell, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer is a major contributor to cancer-related mortality in men, and enzalutamide is a primary treatment option for advanced prostate cancer. Polyamines are ubiquitous amine molecules involved in tumorigenesis, cancer development, and drug resistance. This study aims to explore how spermidine/ spermine N1-acetyltransferase 1 (SAT1)-mediated polyamine metabolism influences prostate cancer progression and enzalutamide sensitivity. Through comprehensive bioinformatics screening, SAT1 was identified as a key regulator negatively associated with spermine abundance in prostate cancer. Analyses of clinical samples showed that increased SAT1 expression was positively linked to higher Gleason scores and more nodal metastases. Functional assays confirmed that knocking down SAT1 suppressed cancer cell proliferation, migration, invasion, and enzalutamide resistance, whereas overexpressing SAT1 enhanced these phenotypes. By promoting spermine catabolism, SAT1 triggered the activation of the JAK1/STAT3 pathway. Xenograft mouse models revealed that SAT1 knockdown inhibited tumor growth and improved the response to enzalutamide via the spermine-JAK1/STAT3 signaling axis. Notably, STAT3 gene was a transcriptional regulator of SAT1. These findings uncover a novel mechanism by which SAT1 facilitates tumor progression and decreases enzalutamide sensitivity, highlighting its potential as a therapeutic target for prostate cancer.
Indexed as
Identifiers
42744967What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.